Skip to NavigationSkip to content

immunotherapy

Sanofi and BioNTech in cancer immunotherapy partnership

R&D

Sanofi and BioNTech have agreed a new multi-year exclusive collaboration and license agreement, to discover and develop up to five cancer immunotherapies.

Under the terms of the agreement, Sanofi will pay $60 million in upfront and near-term milestone payments. BioNTech, which is based in Mainz, Germany, could receive more than $300 million in other development, regulatory and commercial milestones and other payments per product.

Novartis acquires Admune Therapeutics

Novartis is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics, and signing licensing agreements with Palobiofarma and XOMA Corporation.  

Novartis revealed it primarily sought the acquisition of Admune, a clinical-stage biotech company focused on the development and delivery of cytokine therapy drugs for cancer, for the company’s IL-15 agonist program, currently in Phase I clinical trials for metastatic cancer. The fee is not being disclosed. 

FDA grants Opdivo breakthrough status for kidney cancer

Opdivo

The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment.

The FDA’s decision is based on data from BMS’ CheckMate series of studies of Opdivo (nivolumab). The studies have marked the earliest any checkpoint inhibitor has proven itself in a kidney cancer trial. The drug met its primary endpoint by demonstrating an overall survival benefit in patients with metastatic renal cell carcinoma (RCC).

AstraZeneca and Peregrine in immuno-oncology collaboration

Logos

AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies' cancer treatments.

The Phase I/Ib trial will look at AstraZeneca’s durvalumab (MEDI4736) when paired with Peregrine’s bavituximab and chemotherapy, in various solid tumours.

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

Opdivo
NICE now has to assess Opdivo before it can become available for patients

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug in its second indication.

BMS adds lung cancer to advanced melanoma in the list of conditions for which the drug is available, after its launch as a treatment for locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) preceding chemotherapy in adults.

Sanofi, Evotec and Apeiron partner on immuno-oncology

R&D
A scientist at work at Sanofi's immunology laboratory in Thailand

Sanofi is partnering with biotech companies Evotec and Apeiron to develop new cancer immuno-oncology therapies.

The companies say the potential new treatment could fight both tumours and blood cancers by enhancing the anti-tumour activity of the human immune system.

MedImmune and Mirati to partner on lung cancer combo

MedImmune building Cambridge

MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in lung cancer. 

The Phase I/II study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab, in combination with Mirati's investigational anti-cancer, mocetinostat. 

Amgen bets on immunotherapy future

Published on 15/06/15 at 07:43am
Amgen image

When we speak to Tom Lillie he’s brimming with excitement about the future for Amgen in oncology and the future possibilities of new treatments for people with cancers.

Just days after Amgen’s oncolytic immunotherapy – T-VEC (talimogene laherparepvec) – hit the headlines, with noteworthy Phase III trial results in people with skin cancer, Lillie tells Pharmafile he feels that Amgen is set for big things in the field of immunotherapy.

Lilly and AstraZeneca collaborate on cancer trials

MEDI4736 and Cyramza have shown efficacy in lung cancer

AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs.

The trial will look at the safety and effectiveness of different doses of AZ’s potential immunotherapy treatment MEDI4736, in combination with Lilly’s Cyramza (ramucirumab).

Roche lung cancer treatments perform

Roche image

Roche has revealed promising trial data from two lung cancer treatments with one improving survival and the other shrinking tumours. 

Its experimental immunotherapy MPDL3280A has been shown to double the likelihood of survival compared with chemotherapy in people with a specific type of lung cancer.

It is in a new drug class that is designed to help the body's immune system fight cancer by stopping a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1. 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches